Ibuprofen-coumarin skeleton-containing compound and its application

By connecting ibuprofen with coumarin skeleton compounds, a new type of compound with anti-tumor and analgesic activities was formed, and the problem of uncertainty in existing drug resistance and interaction was solved, and effective for tumors and pain was achieved. treat.

CN115368333BActive Publication Date: 2024-11-19HUBEI UNIV OF MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211173554.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-09-26
Publication Date
2024-11-19
Estimated Expiration
2042-09-26

AI Technical Summary

Technical Problem

Existing anti-tumor and analgesic drugs have drug resistance problems and uncertainty in drug interactions when treating tumors and pain, and lack new drugs with diverse structures, high efficiency and low toxicity.

Method used

By connecting ibuprofen to the coumarin skeleton compound through bishydrazide, oxadiazole, and hydrazone bonds, a novel ibuprofen-coumarin skeleton compound with antitumor and analgesic activity, and through specific Synthetic route to prepare the compound.

Benefits of technology

It has achieved significant inhibition and analgesic effects on tumor cells, and has potential application value and is of great significance to the development of new anti-tumor and analgesic drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115368333B_ABST
    Figure CN115368333B_ABST
Patent Text Reader

Abstract

The invention discloses a class of ibuprofen-coumarin skeleton compounds, whose structural formula is as follows: #imgabs0# Such compounds are based on ibuprofen and coumarin with different substituents as pharmacological skeletons, and are prepared by using dihydrazide, acylhydrazone and oxadiazole as key bridge bonds. The preparation method is simple, and the yield is above 80%. Preliminary anti-tumor activity tests show that the compounds have outstanding inhibitory activity on HepG2 liver cancer cells and Hela cervical cancer cells. The activities of compounds 9e, 9i, 10d, 10i, 10e and 10k on HepG2 liver cancer cells and Hela cervical cancer cells are better than those of the commonly used anti-tumor drug gefitinib, among which 10e has the best activity on HepG2 liver cancer cells and Hela cervical cancer cells. Analgesic tests show that the analgesic effect of the compounds is better than or equivalent to that of ibuprofen.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of pharmaceutical chemistry, and specifically relates to an ibuprofen-coumarin pharmacodynamic skeleton compound and a preparation method and application thereof. Background Art

[0002] Tumors and pain pose a threat to human health and survival, and also greatly reduce the quality of life. They are one of the most important social problems facing the world, especially in the mid- and late-stages of cancer development. In recent years, although the clinical approach of "one drug for one disease" has been adopted to treat cancer patients with both chemotherapy and analgesics, that is, the use of "cocktail therapy", which has achieved certain therapeutic effects, it has shortcomings such as drug resistance and uncertainty in the interaction between different drugs. Therefore, for cancer and pain, it is imperative to develop new anti-tumor and analgesic dual-effect drugs with diverse structures, high efficiency and low toxicity.

[0003] Inflammation plays an important role in the occurrence and development of tumors, and cyclooxygenase (COX) is one of the important targets affecting inflammatory responses. Ibuprofen is a common COX inhibitor that can be used clinically to treat a variety of diseases. It is widely used due to its excellent activity and high safety. Since COX-2 is expressed in large quantities in tumor cells, ibuprofen has the effect of inhibiting COX-2. In recent years, researchers have modified the molecular structure of ibuprofen, and the resulting compounds have shown certain anti-tumor activity. Bahareh Shokri's experimental group coupled ibuprofen with a known targeting peptide sequence NGR, in which the NGR peptide can selectively target and bind to the overexpressed aminopeptidase N in tumor blood vessels to exert its effect. The results of the anti-tumor experiment showed that the NGR-coupled form of ibuprofen had a good inhibitory effect on SKOV-3 tumor cells. The study synthesized a series of derivatives by covalently linking α-lipoic acid (ALA) and ibuprofen, and evaluated the cytotoxicity of the newly synthesized ibuprofen derivatives on human glioblastoma cells. The results showed that the derivatives were able to effectively inhibit human glioblastoma cells.

[0004] Coumarin compounds are an important class of pyrone-type oxygen-containing heterocyclic compounds with high bioavailability and low toxicity. Based on their excellent pharmacological activities, some coumarin derivatives have been approved for clinical treatment.

[0005] The splicing of compounds refers to connecting two or more pharmacophores by chemical bonds to obtain new compound molecules. The new molecules obtained usually inherit the pharmacological activity of the pharmacophores involved in the splicing, while reducing the toxic side effects of the pharmacophores. There are two main types of splicing of two pharmacophores: "overlapping" and "linking". Among them, the more common "linking" mainly refers to hybridizing two pharmacophores together through suitable linking groups. Using different linking groups for splicing can constitute different connection strategies.

[0006] There is no report on the compounds related to the present invention. Summary of the invention

[0007] The present invention provides a class of ibuprofen-coumarin skeleton compounds with good anti-tumor activity. The present invention utilizes the natural benzopyrone ring structure of coumarin and utilizes the large dipole moment and hydrogen bonding ability of dihydrazide, oxadiazole and acylhydrazone bonds to bond coumarin and ibuprofen, thereby forming the ibuprofen-coumarin skeleton compounds capable of bonding to a variety of enzymes and receptors in a living body.

[0008] The structural formula of the ibuprofen-coumarin skeleton compound of the present invention is as follows:

[0009]

[0010] Where: Y is selected from (bisacylhydrazide), (Acylhydrazone), (oxadiazole);

[0011] R 1 is selected from H, halogen;

[0012] R 2 Selected from H, halogen, CH3, OH, NO2, aliphatic straight-chain alkane groups containing 1-3 carbon atoms, straight-chain alkoxy groups containing 4-7 carbon atoms, cycloalkoxy groups containing 5-6 carbon atoms, straight-chain alkoxy groups containing 1-3 carbon atoms substituted by straight-chain alkoxy groups containing 1-3 carbon atoms, aliphatic straight-chain amino groups containing 2-4 carbon atoms, and aliphatic branched amino groups containing 4-6 carbon atoms;

[0013] R 3 Selected from aliphatic straight-chain alkane groups containing 1-3 carbon atoms, straight-chain alkoxy groups containing 4-7 carbon atoms, cycloalkoxy groups containing 5-6 carbon atoms, straight-chain alkoxy groups containing 1-3 carbon atoms substituted by straight-chain alkoxy groups containing 1-3 carbon atoms, aliphatic straight-chain amino groups containing 2-4 carbon atoms, and aliphatic branched amino groups containing 4-6 carbon atoms;

[0014] R 4 Selected from H, halogen.

[0015] The ibuprofen-coumarin skeleton-containing compound of the present invention is selected from the following compounds:

[0016]

[0017]

[0018]

[0019]

[0020] The above-mentioned ibuprofen-coumarin skeleton-containing compound is prepared by the following synthesis route: the synthesis route of compounds Ⅰ-9a to Ⅰ-9o is carried out according to the abc synthesis steps, the synthesis route of compounds Ⅰ-10a to Ⅰ-10n is carried out according to the aef synthesis steps, and the synthesis route of compounds Ⅰ-11a to Ⅰ-11i is carried out according to the abcd synthesis steps;

[0021]

[0022] (1) Compounds Ⅰ-9a to Ⅰ-9o are prepared in the presence of a solvent under alkaline conditions;

[0023] The base is selected from one of dimethylamine, diethylamine, dipropylamine and morpholine; the solvent is one or two of dichloromethane, methanol, ethanol, acetonitrile, tetrahydrofuran and dioxane;

[0024] (2) Compounds Ⅰ-10a to Ⅰ-10n were prepared under acidic conditions;

[0025] The acid is selected from one of acetic acid, citric acid, malic acid, tartaric acid, acetic acid, succinic acid and oxalic acid;

[0026] (3) Compounds Ⅰ-11a to Ⅰ-11i are obtained by subjecting compounds Ⅰ-9a to Ⅰ-9o to a dehydration cyclization reaction under the catalysis of a dehydrating agent to introduce an oxadiazole, followed by treatment with an acid-binding agent;

[0027] The dehydrating agent is one of aluminum trichloride, phosphorus oxychloride and phosphorus pentoxide; the acid binding agent is one of potassium carbonate, potassium bicarbonate, sodium carbonate, sodium bicarbonate, potassium hydroxide, sodium hydroxide, triethylamine and pyridine.

[0028] Another object of the present invention is to use the above ibuprofen-coumarin skeleton-containing compound in the preparation of anti-tumor drugs.

[0029] Another object of the present invention is to use the above ibuprofen-coumarin skeleton-containing compound in the preparation of analgesic drugs.

[0030] Advantages and technical effects of the present invention:

[0031] The invention uses ibuprofen, a cyclooxygenase (COX) inhibitor, as a matrix and connects coumarin skeletons with different substituents through diacylhydrazide, oxadiazole and acylhydrazone bonds according to the drug assembly principle to synthesize a novel compound containing a coumarin-ibuprofen skeleton. The preparation method is simple and the yield is high, which is more than 80%. The anti-tumor activity of the compound is preliminarily studied, and an in vitro activity test shows that the ibuprofen-coumarin skeleton compound provided by the invention has obvious anti-tumor activity. An analgesic test shows that the analgesic effect of the compound is better than that of ibuprofen or equivalent to that of ibuprofen. Therefore, the compound of the invention has potential application value as a novel anti-tumor and analgesic drug, and is of great significance for the development of novel anti-tumor and analgesic drugs. DETAILED DESCRIPTION

[0032] The present invention is further described in detail below by way of examples, but the protection scope of the present invention is not limited to the contents described above. The methods in the examples are conventional methods unless otherwise specified, and the reagents used are conventional commercially available reagents or reagents prepared according to conventional methods unless otherwise specified;

[0033] Example 1: Preparation of Compound 9a

[0034] 2.06 g (10 mmol) of ibuprofen hydrazide and 2.09 g (10 mmol) of coumarin carboxylic chloride were weighed and placed in a reactor, and then 20 mL of dry CH2Cl2 was added as a solvent. Under ice bath conditions, anhydrous (C2H5)3N was slowly added dropwise while stirring until the pH of the system became weakly alkaline. The reaction was detected by TLC until all the raw materials disappeared. The reaction solution was concentrated under reduced pressure to remove the solvent, 60 mL of saturated brine was added to the concentrate, and then 60 mL of ethyl acetate was added for extraction. The ethyl acetate phase was collected, dried over anhydrous sodium sulfate, and then concentrated. Silica gel (200-300 mesh) column chromatography was used and eluted with a petroleum ether-ethyl acetate mixture (volume ratio of 1:2). The eluate was collected, concentrated, and dried to obtain the target compound 9a with a yield of 92% as a white solid.

[0035] 1 H NMR(400MHz,DMSO-d6)δ:11.07(s,1H,NH),10.73(s,1H,NH),8.90(s,1H,H-4coumarin),8.04-7.11(m,8H,ArH),3.84-3. 83(m,1H,CH),2.42(d,J=8.0Hz,2H,CH2),1.85-1.80(m,1H,CH),1.41(d,J=4.0Hz,3H,CH3),0.87(d,J=8.0Hz,6H,2×CH3); 13C NMR(100MHz,DMSO-d6)δ:170.69,159.87,158.14,153.89,147.79,139.49,138.58,134.37,130.31,128.8 1,127.08,125.23,118.29,118.02,116.23,44.23,42.19,29.81,22.18,18.42; HRMS(ESI)m / z:Anal.Calcd for C 23 H 25 N2O4([M+H] + ):393.1814,found:393.1833(M + ,100); Anal.RP-UPLC t R =24.588min, purity 97.48%, UV 330nm.

[0036] Example 2: Preparation of Compound 9b

[0037] The preparation method of compound 9b is the same as that of Example 1, except that the coumarin is 6-methylcoumarincarbonyl chloride, to obtain the target compound 9b with a yield of 96% as a white solid.

[0038] 1 H NMR (400MHz, CDCl3) δ: 11.18 (d, J = 8.0Hz, 1H, NH), 9.04 (d, J = 8.0Hz, 1H, NH), 8.73 (s, 1H, H-4 coumarin),7.49-7.10(m,7H,ArH),3.77-3.72(m,1H,CH),2.45-2.41(m,4H,1×CH 1×CH3),1.87-1.81(m,1H,CH),1.58(d,J=8.0Hz,3H,CH3),0.89(d,J=8.0Hz,6H,2×CH3); 13 C NMR(100MHz, CDCl3)δ:170.64,160.70,157.77,152.72,148.69,140.99,137.44,135.83,135.39,129.66,12 9.44,127.39,118.07,116.66,116.57,45.05,44.60,30.18,22.42,20.77,18.55; HRMS(ESI)m / z:Anal.Calcd for C 24 H 27 N2O4([M+H] +):407.1971,found:407.1970(M + ,100); Anal.RP-UPLC t R =25.447min, purity 97.19%, UV330nm.

[0039] Example 3: Preparation of Compound 9c

[0040] The preparation method of compound 9c is the same as that of Example 1, except that the coumarin is 7-hydroxycoumarin carboxylic chloride, to obtain the target compound 9c with a yield of 82% as a yellow solid.

[0041] 1 H NMR(400MHz, CDCl3)δ:11.02(s,1H,NH),10.63(s,1H,NH),8.82(s,1H,H-4coumarin),7.96-6.82(m,7H,ArH),3.82(t, J=8.0Hz,1H,CH),2.41(m,2H,1×CH2),1.84-1.79(m,1H,CH),1.39(d,J=8.0Hz,3H,CH3),0.86(d,J=8.0Hz,6H,2×CH3); 13 C NMR(100MHz,DMSO-d6)δ:170.58,164.50,162.28,160.65,158.67,156.45,148.46,139.45,138.60,132.0 9,128.78,127.07,114.69,110.84,101.90,44.23,42.16,29.16,22.16,18.41; HRMS(ESI)m / z:Anal.Calcd for C 23 H 25 N2O5([M+H] + ):409.1763,found:409.1764(M + ,100); Anal.RP-UPLC t R =22.876min, purity 96.05%, UV 330nm.

[0042] Example 4: Preparation of Compound 9d

[0043] The preparation method of compound 9d is the same as that of Example 1, except that coumarin is 6-chlorocoumarincarbonyl chloride, to obtain the target compound 9d with a yield of 92% as a white solid.

[0044] 1H NMR (400MHz, CDCl3) δ: 11.05 (d, J = 4.0Hz, 1H, NH), 8.74 (s, 1H, NH), 8.40 (d, J = 8.0Hz, 1H, H-4 coumarin),7.65-7.13(m,7H,ArH),3.71(q,J=8.0Hz,1H,CH),2.46(d,J=8.0Hz,2H ,CH2),1.89-1.82(m,1H,CH),1.61-1.58(m,3H,CH3),0.91(d,J=8.0Hz,6H,2×CH3); 13 C NMR(100MHz, CDCl3)δ:170.53,159.93,157.07,152.81,147.47,141.26,137.07,134.51,130.90,129.82 ,128.82,127.40,119.24,118.36,117.95,45.04,44.88,30.19,22.42,18.44; HRMS(ESI)m / z:Anal.Calcd for C 23 H 24 ClN2O4([M+H] + ):427.1425,found:427.1424(M + ,100); Anal.RP-UPLC t R =25.773min, purity 96.37%, UV 330nm.

[0045] Example 5: Preparation of Compound 9e

[0046] The preparation method of compound 9e is the same as that of Example 1, except that coumarin is 6-fluorocoumarincarbonyl chloride, to obtain the target compound 9e with a yield of 90% as a white solid.

[0047] 1 H NMR(400MHz,DMSO-d6)δ:11.07(s,1H,NH),10.73(s,1H,NH),8.85(s,1H,H-4coumarin),7.92-7.09(m,7H,ArH),3.81(q,J= 8.0Hz,1H,CH),2.41(d,J=8.0Hz,2H,CH2),1.84-1.77(m,1H,CH),1.38(d,J=8.0Hz,3H,CH3),0.84(d,J=8.0Hz,6H,2×CH3); 13CNMR(100MHz,DMSO-d6)δ:170.68,159.57,157.89,150.32,146.69,139.49,138.55,128.81,127.07,119. 19,118.39,118.30,115.26,115.01,99.49,44.22,42.18,29.61,22.17,18.42; HRMS(ESI)m / z:Anal.Calcd for C 23 H 24 FN2O4([M+H] + ):411.1720,found:411.1722(M + ,100); Anal.RP-UPLC t R =24.828min, purity 98.92%, UV 330nm.

[0048] Example 6: Preparation of Compound 9f

[0049] The preparation method of compound 9f is the same as that of Example 1, except that the coumarin is 7-butoxycoumarin carboxylic acid chloride, to obtain the target compound 9f with a yield of 91% as a white solid.

[0050] 1 H NMR (400MHz, DMSO-d6) δ: 11.04 (d, J=8.0Hz, 1H, NH), 10.65 (d, J=4.0Hz, 1H, NH), 8.87 (s, 1H, H-4 coumarin),7.94-7.05(m,7H,ArH),4.14(t,J=8.0Hz,1H,CH),3.82(q,J=8.0Hz,2H,CH2),2.42(d,J=8.0Hz,2H,CH2),1.83-1.71(m,3H,1×CH 1×CH2),1.50-1.43(m,2H,CH2),1.37(d,J=8.0Hz,3H,CH3),0.95(t,J=8.0Hz,3H,CH3)0.87(d,J=8.0Hz,6H,2×CH3); 13C NMR(100MHz,DMSO-d6)δ:171.09,164.03,160.95,158.97,156.77,148.75,139.97,132.16,129.31,127.57,114.60, 114.04,112.41,101.22,68.90,44.72,42.66,30.87,30.11,22.66,19.11,18.92,14.11; HRMS(ESI)m / z:Anal.Calcd for C 27 H 33 N2O5([M+H] + ):465.2389,found:465.2393(M + ,100); Anal.RP-UPLC t R =28.293min, purity99.50%, UV 330nm.

[0051] Example 7: Preparation of Compound 9g

[0052] The preparation method of compound 9g is the same as that of Example 1, except that coumarin is 6-nitrocoumarincarbonyl chloride, to obtain the target compound 9g with a yield of 84% as a yellow solid.

[0053] 1 H NMR(400MHz,DMSO-d6)δ:11.02(s,1H,NH),10.63(s,1H,NH),9.01-7.10(m,8H,ArH),3.80(q,J=8.0Hz,1H,C H),2.41(d,J=8.0Hz,2H,CH2),1.84-1.79(m,1H,CH),1.39(d,J=4.0Hz,CH3),0.86(d,J=4.0Hz,6H,2×CH3); 13 C NMR(100MHz,DMSO-d6)δ:170.89,158.78,157.91,157.30,146.41,143.94,139.51,138.54,128.82,128.31, 127.08,126.00,120.44,118.68,117.84,44.22,42.24,29.61,22.16,18.41; HRMS(ESI)m / z:Anal.Calcdfor C 23 H 24 N3O6([M+H] + ):438.1665,found 438.1665(M +,100); Anal.RP-UPLC t R =24.938min, purity 99.64%, UV 330nm.

[0054] Example 8: Preparation of Compound 9h

[0055] The preparation method of compound 9h is the same as that of Example 1, except that coumarin is 6,8-dichlorocoumarincarbonyl chloride, to obtain the target compound 9h with a yield of 86% as a yellow solid.

[0056] 1 H NMR (400MHz, DMSO-d6) δ: 11.05 (s, 1H, NH), 10.64 (s, 1H, NH), 8.83 (s, 1H, H-4coumarin), 8.15-7.10 (m, 6H, ArH), 3.80 (q, J= 8.0Hz,1H,CH),2.42(d,J=8.0Hz,2H,CH2),1.85-1.80(m,1H,CH),1.40(d,J=8.0Hz,3H,CH3),0.87(d,J=4.0Hz,6H,2×CH3); 13 CNMR(100MHz,DMSO-d6)δ:170.82,158.47,157.73,148.32,146.10,139.50,138.52,132.95,128.81,128.74,128.20,127.08 120.88,120.74,120.31,44.22,42.21,29.61,22.16,18.41; HRMS(ESI)m / z:Anal.Calcd for C 23 H 23 Cl2N2O4([M+H] + ):461.1035,found:461.1034(M + ,100); Anal.RP-UPLC t R =26.959min, purity 99.15%, UV 330nm.

[0057] Example 9: Preparation of Compound 9i

[0058] The preparation method of compound 9i is the same as that of Example 1, except that the coumarin is 6,8-dibromocoumarincarbonyl chloride, to obtain the target compound 9i with a yield of 90% as a white solid.

[0059] 1H NMR(400MHz, CDCl3)δ:10.09(s,1H,NH),8.69(s,1H,H-4 coumarin),8.27(s,1H,NH),8.02-7.14(m,6H,ArH),3.70(q,J=8.0Hz,1H,CH),2.46(d,J=8.0 Hz,2H,CH2),1.89-1.82(m,1H,CH),1.60(d,J=4.0Hz,3H,CH3),0.91(d,J=4.0Hz,6H,2×CH3); 13 C NMR(100MHz, CDCl3)δ:170.63,158.98,156.70,150.28,147.13,141.32,139.84,136.99,131.09,129.86 ,127.42,120.45,118.62,118.06,111.49,45.04,44.96,30.19,22.42,18.40; HRMS(ESI)m / z:Anal.Calcd for C 23 H 23 Br2N2O4([M+H] + ):549.0025,found:549.0024(M + ,100),UV 330nm.

[0060] Example 10: Preparation of Compound 9j

[0061] The preparation method of compound 9j is the same as that of Example 1, except that the coumarin is 7-pentyloxycoumarin carboxylic chloride, to obtain the target compound 9j with a yield of 94% as a white solid.

[0062] 1 H NMR (400MHz, CDCl3) δ: 11.01 (d, J = 4.0Hz, 1H, NH), 8.74 (s, 1H, H-4 coumarin),8.23(d,J=8.0Hz,1H,NH),7.56-6.84(m,7H,ArH),4.05(t,J=8.0Hz,2H ,CH2),3.70(q,J=8.0Hz,1H,CH),2.46(d,J=8.0Hz,2H,CH2),1.89-1.80(m,3H,1×CH 1×CH2),1.59(d,J=8.0Hz,3H,CH3),1.47-1.37(m,4H,2×CH2),0.96-0.90(m,9H,3×CH3); 13C NMR (100MHz, CDCl3) δ: 170.45, 164.97, 158.38, 156.92, 148.69, 141.18, 137.20, 130.99, 129.80, 127.42, 114.70, 112. 76,111.97,110.86,69.10,45.05,44.95,30.18,28.56,28.05,22.42,22.40,18.46,14.00; HRMS(ESI)m / z:Anal.Calcd for C 28 H 35 N2O5([M+H] + ):479.2546,found:479.2543(M + ,100); Anal.RP-UPLC t R =29.468min, purity 96.68%, UV 330nm.

[0063] Example 11: Preparation of Compound 9k

[0064] The preparation method of compound 9k is the same as that of Example 1, except that the coumarin is 7-hexyloxycoumarin carboxylic chloride, to obtain the target compound 9k with a yield of 88% as a white solid.

[0065] 1 H NMR (400MHz, CDCl3) δ: 11.02 (d, J = 8.0Hz, 1H, NH), 8.74 (s, 1H, H-4 coumarin),8.38(d,J=8.0Hz,1H,NH),7.55-6.84(m,7H,ArH),4.05(t,J=8.0Hz,2H ,CH2),3.70(q,J=8.0Hz,1H,CH),2.46(d,J=8.0Hz,2H,CH2),1.89-1.79(m,3H,1×CH 1×CH2),1.63-1.58(m,4H,2×CH2),1.49-1.44(m,4H,2×CH2),1.36-1.34(m,3H,CH3),0.93-0.90(m,9H,3×CH3); 13CNMR(100MHz, CDCl3)δ:170.47,164.96,161.01,158.37,156.91,148.68,141.14,137.25,130.99,129.77,127.41,114.70,112 .76,111.96,100.86,69.12,45.05,44.88,31.49,30.18,28.83,25.60,22.57,22.43,18.48,14.03; HRMS(ESI)m / z:Anal.Calcd forC 29 H 37 N2O5([M+H] + ):493.2702,found:493.2707(M + ,100); Anal.RP-UPLC t R =30.513min, purity 99.92%, UV 330nm.

[0066] Example 12: Preparation of Compound 91

[0067] The preparation method of compound 91 is the same as that of Example 1, except that the coumarin is 7-cyclohexylcoumarin carboxylic chloride, to obtain the target compound 9 with a yield of 86% as a white solid.

[0068] 1 H NMR(400MHz, CDCl3)δ:11.04(s,1H,NH),8.72(s,1H,H-4 coumarin),8.46(s,1H,NH),7.54-6.84(m,7H,ArH),4.39-4.34(m,1H,CH),3.71(q,J=8.0Hz,1H,CH),2.45(d,J=8.0Hz,2H,CH2),2.02-1.66 and 1.46-1.32(m,10H,5×CH2 1×CH3),1.59(d,J=8.0Hz,3H,CH3),0.91(d,J=8.0Hz,6H,2×CH3); 13C NMR(100MHz, CDCl3)δ:170.47,163.86,161.05,158.41,156.95,148.64,141.11,137.29,131.06,129.75,127.40,115. 40,112.54,111.76,101.68,76.64,45.05,44.85,31.37,30.19,25.35,23.54,22.43,18.49; HRMS(ESI)m / z:Anal.Calcd for C 29 H 35 N2O5([M+H] + ):491.2546,found:491.2549(M + ,100);Anal.RP-UPLCt R =29.335min, purity 99.65%, UV 330nm.

[0069] Example 13: Preparation of Compound 9m

[0070] The preparation method of compound 9m is the same as that of Example 1, except that coumarin is 7-methoxyethoxycoumarin carboxylic chloride, to obtain the target compound 9m with a yield of 93% as a white solid.

[0071] 1 H NMR (400MHz, CDCl3) δ: 11.01 (d, J = 8.0Hz, 1H, NH), 8.83 (s, 1H, H-4 coumarin),8.49(d,J=4.0Hz,1H,NH),7.56-6.89(m,7H,ArH),4.21(t,J=8.0Hz,1H,CH),3.71(q,J=8.0Hz,H,CH),3.46 (s,3H,CH3),2.45(d,J=8.0Hz,2H,CH2),1.89-1.83(m,1H,CH),1.59(d,J=4.0Hz,3H,CH3),0.91(d,J=4.0Hz,3H,CH3); 13C NMR(100MHz, CDCl3)δ:170.53,164.49,160.91,158.28,156.74,148.60,141.11,137.30,131.03,129.74,127.41,1 14.69,113.14,112.29,101.10,70.51,68.27,59.32,45.05,44.84,30.17,22.42,18.49; HRMS(ESI)m / z:Anal.Calcd for C 26 H 31 N2O6([M+H] + ):467.2182; found:467.2182(M + ,100);Anal.RP-UPLCt R =24.565min, purity 99.35%, UV 330nm.

[0072] Example 14: Preparation of Compound 9n

[0073] The preparation method of compound 9n is the same as that of Example 1, except that the coumarin is 6-ethylcoumarin carboxylic chloride, to obtain the target compound 9n with a yield of 94% as a white solid.

[0074] 1 H NMR (400MHz, CDCl3) δ: 11.18 (d, J = 8.0Hz, 1H, NH), 9.04 (d, J = 8.0Hz, 1H, NH), 8.73 (s, 1H, H-4 coumarin),7.49-7.10(m,7H,ArH),3.77-3.72(m,1H,CH),2.7-2.9(d,2H,CH2),2.45-2.41(m,4H,1×CH 1×CH3),1.87-1.81(m,1H,CH),1.58(d,J=8.0Hz,3H,CH3),0.89(d,J=8.0Hz,6H,2×CH3); 13 C NMR(100MHz, CDCl3)δ:170.64,160.70,157.77,152.72,148.69,140.99,137.44,135.83,135.39,129.66,12 9.44,127.39,118.07,116.66,116.57,45.05,44.60,30.18,22.42,20.77,18.55; HRMS(ESI)m / z:Anal.Calcd for C 24 H 27N2O4([M+H] + ):421.1971,found:420.1970(M + ,100); Anal.RP-UPLC t R =25.447min, purity97.19%, UV 330nm.

[0075] Example 15: Preparation of Compound 9o

[0076] The preparation method of compound 9o is the same as that of Example 1, except that the coumarin is 7-cyclopentyloxycoumarin carboxylic chloride, to obtain the target compound 9o with a yield of 89% as a white solid.

[0077] 1 H NMR(400MHz, CDCl3)δ:11.04(s,1H,NH),8.72(s,1H,H-4 coumarin),8.46(s,1H,NH),7.54-6.84(m,7H,ArH),4.39-4.34(m,1H,CH),3.71(q,J=8.0Hz,1H,CH),2.45(d,J=8.0Hz,2H,CH2),2.02-1.66 and 1.46-1.32(m,11H,4×CH2 1×CH3),1.59(d,J=8.0Hz,3H,CH3),0.91(d,J=8.0Hz,6H,2×CH3); 13 C NMR(100MHz, CDCl3)δ:170.47,163.86,161.05,158.41,156.95,148.64,141.11,137.29,131.06,129.75,127.40,115. 40,112.54,111.76,101.68,76.64,45.05,44.85,31.37,30.19,25.35,23.54,22.43,18.49; HRMS(ESI)m / z:Anal.Calcd for C 29 H 35 N2O5([M+H] + ):479.1639,found:479.1639(M + ,100);Anal.RP-UPLCt R =29.335min, purity 99.65%, UV 330nm.

[0078] Example 16: Preparation of Compound 10a

[0079] 2.06 g (10 mmol) of ibuprofen hydrazide and 2.06 g (10 mmol) of 3-acetyl-6-fluorocoumarin were weighed and placed in a reactor. 20 mL of EtOH was added as a solvent, and a few drops of glacial acetic acid (HAc) were added dropwise as a catalyst. The mixture was stirred under reflux at 60° C. and the reaction was detected by TLC until all the raw materials disappeared. The reaction solution was concentrated under reduced pressure to remove the solvent. 60 mL of saturated sodium bicarbonate aqueous solution was added to the concentrate, and then 60 mL of ethyl acetate was added for extraction. The ethyl acetate phase was collected, dried over anhydrous sodium sulfate, concentrated, and eluted with a silica gel (200-300 mesh) column chromatography. The eluent was a mixture of petroleum ether and ethyl acetate (petroleum ether:ethyl acetate volume ratio = 1:3) to obtain the target compound 10a with a yield of 89% as a yellow solid.

[0080] 1 H NMR(400MHz, CDCl3)δ:8.67 and 8.34(s,1H,NH and OH,keto-enoltautomerism,keto(-CONH-) / enol(-HOC=N-)ratio 33 / 67),8.08 and 7.57(s,1H,H-4coumarin),7.33-7.12(m,7H,ArH),4.56-4.51 and 3.78-3.76(m,1H,CH),2.48(d,J=8.0Hz,2H,CH2),2.17 and 1.90(s,3H,CH3),1.89-1.84(m,1H,CH),1.66 and 1.51(d,J=8.0Hz,3H,CH3),0.91(d,J=4.0Hz,6H,2×CH3); 13 C NMR(100MHz, CDCl3)δ:176.32,160.09,157.65,150.18,140.29,138.94,130.12,129.33,127.85,127.52,19 9.83,118.23,118.15,113.66,113.42,45.10,42.09,30.24,22.44,18.83,14.21; HRMS(ESI)m / z:Anal.Calcd forC 24 H 26 FN2O3([M+H] + ):409.1927,found:409.1931(M + ,100); Anal.RP-UPLC t R (keto)=25.147min,t R(enol)=26.788min, purity 99.62%, UV 330nm.

[0081] Example 17: Preparation of Compound 10b

[0082] The preparation process is the same as that of Example 16, except that the coumarin is 3-acetyl-7-butoxycoumarin, to obtain the target compound 10b with a yield of 95% as a yellow solid.

[0083] 1 H NMR(400MHz, CDCl3)δ:8.71 and 8.36(s,1H,NH and OH,keto-enoltautomerism,keto(-CONH-) / enol(-HOC=N-)ratio 35 / 65),8.09 and 7.64(s,1H,H-4coumarin),7.41-7.11(m,7H,ArH),4.59-4.57 and 3.77-3.76(m,1H,CH),4.06-3.99(m,2H,CH2),2.49-2.46(m,2H,CH2),2.17 and 1.91(s,3H,CH3),1.90-1.80(m,3H,1×CH 1×CH2),1.66 and 1.51(d,J=4.0Hz,3H,CH3),1.57-1.53 ​​and 1.50-1.47(m,2H,CH2),1.02-0.97(m,3H,CH3),0.90(d,J=8.0Hz,6H,2×CH3); 13 C NMR(100MHz, CDCl3)δ:176.36,162.98,160.37,156.03,145.22,141.66,140.13,139.02,130.44,129.43,129.25,127.58, 113.60,112.54,100.91,68.51,45.12,41.88,30.98,30.24,22.48,22.31,19.18,18.76,13.80; HRMS(ESI)m / z:Anal.Calcd for C 28 H 35 N2O4([M+H] + ):463.2597,found:463.2598(M + ,100); Anal.RP-UPLC t R (keto)=28.818min,t R(enol)=30.558min, purity 99.97%, UV 330nm.

[0084] Example 18: Preparation of Compound 10c

[0085] The preparation process was the same as that of Example 16, except that the coumarin was 3-acetyl-7-pentyloxycoumarin, and the target compound 10c was obtained with a yield of 96% as a white solid.

[0086] 1 H NMR(400MHz, CDCl3)δ:8.57 and 8.30(s,1H,NH and OH,keto-enoltautomerism,keto(-CONH-) / enol(-HOC=N-)ratio 33 / 67),8.10 and 7.64(s,1H,H-4coumarin),7.42-6.77(m,7H,ArH),4.58-4.56 and 3.77-3.75(m,1H,CH),4.05-3.99(m,2H,CH2),2.50-2.46(m,2H,CH2),2.16 and 1.90(s,3H,CH3),1.88-1.82(m,3H,1×CH 1×CH2),1.66 and 1.51(d,J=8.0Hz,3H,CH3),1.47-1.38(m,4H,2×CH2),0.97-0.94(m,3H,CH3),0.90(d,J=8.0Hz,6H,2×CH3); 13 CNMR(100MHz, CDCl3)δ:176.26,163.00,160.37,156.04,141.69,140.15,139.00,130.07,129.44,129.27,127.58,122.90,113 .62,112.54,100.91,68.82,45.12,41.90,30.24,28.66,28.10,22.42,22.31,18.75,14.26,14.00; HRMS(ESI)m / z:Anal.Calcd for C 29 H 37 N2O4([M+H] + ):477.2753,found:477.2752(M + ,100); Anal.RP-UPLC t R (keto)=29.992min,t R(enol)=31.758min, purity 99.30%, UV 330nm.

[0087] Example 19: Preparation of Compound 10d

[0088] The preparation process was the same as that of Example 16, except that the coumarin was 3-acetyl-7-(2-methoxy)ethoxycoumarin, to obtain the target compound 10d with a yield of 94% as a white solid.

[0089] 1 H NMR(400MHz, CDCl3)δ:8.63 and 8.35(s,1H,NH and OH,keto-enoltautomerism,keto(-CONH-) / enol(-HOC=N-)ratio 34 / 66),8.09 and 7.64(s,1H,H-4coumarin),7.42-6.81(m,7H,ArH),4.58-4.56 and 3.79-3.78(m,1H,CH),4.21-4.17(m,2H,CH2),3.81-3.79(m,2H,CH2)2.50-2.46(m,2H,CH2),2.17 and 1.91(s,3H,CH3),1.88-1.85(m,1H,CH),1.66 and 1.51(d,J=4.0Hz,3H,CH3),0.90(d,J=8.0Hz,6H,2×CH3); 13 CNMR(100MHz, CDCl3)δ:176.33,162.54,155.90,145.09,141.56,140.15,139.00,130.06,129.48,129.27,127.58,123. 27,113.63,112.89,101.12,70.64,68.02,59.32,45.12,41.89,30.23,22.45,18.75,14.29; HRMS(ESI)m / z:Anal.Calcd for C 27 H 33 N2O5([M+H] + ):465.2389,found:465.2389(M + ,100); Anal.RP-UPLC t R (keto)=24.668min,t R (enol)=26.070min, purity 98.75%, UV 330nm.

[0090] Example 20: Preparation of Compound 10e

[0091] The preparation process is the same as that of Example 16, except that the coumarin is 3-acetyl-6,8-dibromocoumarin, and the target compound 10e is obtained with a yield of 89% as a white solid.

[0092] 1 H NMR(400MHz, CDCl3)δ:8.92 and 8.43(s,1H,NH and OH,keto-enoltautomerism,keto(-CONH-) / enol(-HOC=N-)ratio 30 / 70),8.00 and 7.89(s,1H,H-4coumarin),7.59-7.11(m,7H,ArH),4.53-4.48 and 3.78-3.76(m,1H,CH),2.49(d,J=8.0Hz,2H,CH2),2.18 and 1.90(s,3H,CH3),1.89-1.85(m,1H,CH),1.66 and 1.50(d,J=4.0Hz,3H,CH3),0.91-0.90(m,6H,2×CH3); 13 C NMR(100MHz, CDCl3)δ:176.45,158.29,149.79,143.68,140.22,139.49,139.02,137.51,130.12,129.90,12 9.36,127.47,121.36,117.14,111.09,45.11,42.23,30.24,22.44,18.89,14.21; HRMS(ESI)m / z:Anal.Calcd forC 24 H 25 Br2N2O3([M+H] + ):547.0232,found:547.0235(M + ,100); Anal.RP-UPLC t R =30.123min, purity 99.54%, UV 330nm.

[0093] Example 21: Preparation of Compound 10f

[0094] The preparation process is the same as that of Example 16, except that the coumarin is 3-acetyl-7-hydroxycoumarin, to obtain the target compound 10f with a yield of 87% as a yellow solid.

[0095] 1H NMR(400MHz, CDCl3)δ:9.77(s,1H,Ar-OH),8.70 and 8.53(s,1H,NH and OH,keto-enol tautomerism,keto(-CONH-) / enol(-HOC=N-)ratio 20 / 80),7.63 and 7.31(s,1H,H-4coumarin),7.29-6.96(m,7H,ArH),3.85-3.80 and 3.76-3.71(m,1H,CH),2.49(d,J=8.0Hz,2H,CH2),2.16 and 1.92(s,3H,CH3),1.87-1.84(m,H,CH),1.68 and 1.50(d,J=8.0Hz,3H,CH3),0.89(d,J=8.0Hz,6H,2×CH3); 13 C NMR(100MHz, CDCl3)δ:172.54,161.90,160.42,155.36,152.20,142.57,141.79,136.76,130.13,129.73,12 7.58,120.58,114.34,110.93,103.46,45.68,44.98,30.23,22.31,18.04,14.69; HRMS(ESI)m / z:Anal.Calcd for C 24 H 27 N2O4([M+H] + ):407.1971,found:407.1970(M + ,100);Anal.RP-UPLCt R (keto)=22.742min,t R (enol)=23.904min, purity 99.40%, UV 330nm.

[0096] Example 22: Preparation of Compound 10g

[0097] The preparation process is the same as that of Example 16, except that the coumarin is 3-acetyl-7-diethylaminocoumarin, and 10 g of the target compound is obtained with a yield of 97% as a yellow solid.

[0098] 1H NMR(400MHz, CDCl3)δ:8.77 and 8.41(s,1H,NH and OH,keto-enoltautomerism,keto(-CONH-) / enol(-HOC=N-)ratio 37 / 63),8.04 and 7.62(s,1H,H-4coumarin),7.31-6.43(m,7H,ArH),4.63-4.58 and 3.78-3.76(m,1H,CH),3.47-3.38(m,4H,2×CH2),2.46(d,J=8.0Hz,2H,CH2),2.18 and 1.94(s,3H,CH3),1.88-1.84(m,1H,CH),1.65 and 1.51(d,J=4.0Hz,3H,CH3),1.27-1.19(m,6H,2×CH3),0.90(d,J=8.0Hz,6H,2×CH3); 13 C NMR(100MHz, CDCl3)δ:176.36,161.15,156.96,151.22,142.09,140.01,139.14,129.94,129.67,129.20,127.63,1 18.98,109.29,108.51,97.00,45.13,44.93,41.77,30.21,22.46,22.31,14.40,12.48; HRMS(ESI)m / z:Anal.Calcd for C 28 H 36 N3O3([M+H] + ):462.2757,found:462.2760(M + ,100); Anal.RP-UPLC t R (keto)=27.011min,t R (enol)=28.871min, purity 99.24%, UV 400nm.

[0099] Example 23: Preparation of Compound 10h

[0100] The preparation process is the same as that of Example 16, except that the coumarin is 3-acetyl-6-methylcoumarin, and the target compound 10h is obtained with a yield of 94% as a white solid.

[0101] 1H NMR(400MHz, CDCl3)δ:8.81 and 8.37(s,1H,NH and OH,keto-enoltautomerism,keto(-CONH-) / enol(-HOC=N-)ratio 32 / 68),8.07 and 7.61(s,1H,H-4coumarin),7.38-7.12(m,7H,ArH),4.60-4.54 and 3.78-3.76(m,1H,CH),2.49-2.47(m,2H,CH2),2.45-2.39(m,3H,CH3),2.19 and 1.91(s,3H,CH3),1.88-1.83(m,1H,CH),1.66and 1.51(d,J=8.0Hz,3H,CH3),0.91(d,J=8.0Hz,6H,2×CH3); 13 C NMR(100MHz, CDCl3)δ:178.44,160.18,152.19,145.00,141.44,140.13,138.98,134.43,133.35,130.08,129.29 ,127.59,.126.66,118.82,116.31,45.14,41.92,30.25,22.48,20.83,18.79,14.40; HRMS(ESI)m / z:Anal.Calcd for C 25 H 29 N2O3([M+H] + ):405.2178,found:405.2181(M + ,100); Anal.RP-UPLC t R (keto)=25.734min,t R (enol)=27.580min, purity 98.55%, UV 330nm.

[0102] Example 24: Preparation of Compound 10i

[0103] The preparation process is the same as that of Example 16, except that the coumarin is 3-acetyl-6,8-dichlorocoumarin, and the target compound 10i is obtained with a yield of 89% as a white solid.

[0104] 1H NMR(400MHz, CDCl3)δ:8.66 and 8.35(s,1H,NH and OH,keto-enoltautomerism,keto(-CONH-) / enol(-HOC=N-)ratio 34 / 66),8.04 and 7.61(s,1H,H-4coumarin),7.47-7.12(m,7H,ArH),4.53-4.48 and 3.78-3.76(m,1H,CH),2.49(d,J=4.0Hz,2H,CH2),2.17 and 1.90(s,3H,CH3),1.90-1.87(m,1H,CH),1.66 and 1.51(d,J=8.0Hz,3H,CH3),0.91-0.90(d,J=4.0Hz,6H,2×CH3); 13 C NMR(100MHz, CDCl3)δ:176.24,148.27,139.60,132.22,132.06,130.16,129.91,129.37,128.50,127.47,12 6.50,126.15,122.53,120.89,104.48,45.09,42.22,30.25,22.45,18.89,14.05; HRMS(ESI)m / z:Anal.Calcd for C 24 H 25 Cl2N2O3([M+H] + ):459.1242,found:459.1246(M + ,100); Anal.RP-UPLC t R (keto)=27.339min,t R (enol)=29.455min, purity 99.55%, UV 330nm.

[0105] Example 25: Preparation of Compound 10j

[0106] The preparation process is the same as that of Example 16, except that the coumarin is 3-acetylcoumarin, and the target compound 10j is obtained with a yield of 95% as a white solid.

[0107] 1H NMR(400MHz, CDCl3)δ:8.85 and 8.33(s,1H,NH and OH,keto-enoltautomerism,keto(-CONH-) / enol(-HOC=N-)ratio 34 / 66),8.14 and 7.68(s,1H,H-4coumarin),7.59-7.12(m,8H,ArH),4.57-4.55 and 3.78-3.76(m,1H,CH),2.50-2.47(m,2H,CH2),2.18 and 1.91(s,3H,CH3),1.89-1.83(m,1H,CH),1.66 and 1.51(d,J=8.0Hz,3H,CH3),0.91(d,J=4.0Hz,6H,2×CH3); 13 C NMR(100MHz, CDCl3)δ:176.31,159.95,154.03,144.68,141.41,140.22,138.94,132.29,130.10,129.30,12 8.47,127.58,124.76,119.08,116.63,45.12,41.98,30.26,22.46,22.32,18.79; HRMS(ESI)m / z:Anal.Calcd forC 24 H 27 N2O3([M+H] + ):391.2022,found:391.2025(M + ,100); Anal.RP-UPLC t R (keto)=24.710min,t R (enol)=26.277min, purity 99.55%, UV 330nm.

[0108] Example 26: Preparation of Compound 10k

[0109] The preparation process was the same as that of Example 16, except that the coumarin was 3-acetyl-6-chlorocoumarin, and the target compound 10k was obtained with a yield of 93% as a white solid.

[0110] 1H NMR(400MHz, CDCl3)δ:8.65 and 8.42(s,1H,NH and OH,keto-enoltautomerism,keto(-CONH-) / enol(-HOC=N-)ratio 29 / 71),8.33 and 8.05(s,1H,H-4coumarin),7.64-7.13(m,7H,ArH),4.55-4.50 and 3.78-3.76(m,1H,CH),2.49(d,J=8.0Hz,2H,CH2),2.17 and 1.90(s,3H,CH3),1.87-1.84(m,1H,CH),1.66 and 1.51(d,J=8.0Hz,3H,CH3),0.91(d,J=8.0Hz,6H,2×CH3); 13 C NMR (100MHz, CDCl3) δ: 176.28, 159.33, 152.34, 144.08, 140.04, 138.96, 134.28, 132.13, 130.00, 129.35, 127. 81,127.62,127.50,120.10,118.20,118.02,30.25,22.45,18.85,17.99,14.18; HRMS(ESI)m / z:Anal.Calcdfor C 24 H 26 ClN2O3([M+H] + ):425.1632,found:425.1636(M + ,100); Anal.RP-UPLC t R (keto)=19.105min,t R (enol)=28.065min, purity 96.19%, UV 330nm.

[0111] Example 27: Preparation of Compound 101

[0112] The preparation process is the same as that of Example 16, except that the coumarin is 3-acetyl-7-propylaminocoumarin, and the target compound 101 is obtained with a yield of 94% as a yellow solid.

[0113] 1H NMR(400MHz, CDCl3)δ:8.77 and 8.41(s,1H,NH and OH,keto-enoltautomerism,keto(-CONH-) / enol(-HOC=N-)ratio 37 / 63),8.04 and 7.62(s,1H,H-4coumarin),7.31-6.43(m,7H,ArH),4.63-4.58 and 3.78-3.76(m,1H,CH),3.47-3.38(m,4H,2×CH2),2.46(d,J=8.0Hz,2H,CH2),2.18 and 1.94(s,3H,CH3),1.88-1.84(m,1H,CH),1.64(d,J=4.0Hz,3H,CH3),1.27-1.19(m,6H,2×CH3),0.90(d,J=8.0Hz,6H,2×CH3); 13 CNMR(100MHz, CDCl3)δ:176.36,161.15,156.96,151.22,142.09,140.01,139.14,129.94,129.67,129.20,127.63, 118.98,109.29,108.51,97.00,45.13,44.93,41.77,30.21,22.46,22.31,14.40,12.48; HRMS(ESI)m / z:Anal.Calcd for C 28 H 36 N3O3([M+H] + ):447.2757,found:447.2760(M + ,100); Anal.RP-UPLC t R (keto)=27.011min,t R (enol)=28.871min, purity 99.24%, UV 400nm.

[0114] Example 28: Preparation of Compound 10m

[0115] The preparation process is the same as that of Example 16, except that the coumarin is 3-acetyl-7-dipropylaminocoumarin, and the target compound 10m is obtained with a yield of 90% as a yellow solid.

[0116] 1H NMR(400MHz, CDCl3)δ:8.77 and 8.41(s,1H,NH and OH,keto-enoltautomerism,keto(-CONH-) / enol(-HOC=N-)ratio 37 / 63),8.04 and 7.62(s,1H,H-4coumarin),7.31-6.43(m,7H,ArH),4.63-4.58 and 3.78-3.76(m,1H,CH),3.47-3.38(m,4H,2×CH2),2.87-3.08(m,4H,2×CH2),2.46(d,J=8.0Hz,2H,CH2),2.18 and 1.94(s,3H,CH3),1.88-1.84(m,1H,CH),1.65 and 1.51(d,J=4.0Hz,3H,CH3),1.27-1.19(m,6H,2×CH3),0.90(d,J=8.0Hz,6H,2×CH3); 13 CNMR(100MHz, CDCl3)δ:176.36,161.15,156.96,151.22,142.09,140.01,139.14,129.94,129.67,129.20,127.63,11 8.98,109.29,108.51,97.00,45.13,44.93,41.77,30.21,22.46,22.31,14.40,12.48; HRMS(ESI)m / z:Anal.Calcdfor C 28 H 36 N3O3([M+H] + ):490.1548,found:490.1548(M + ,100); Anal.RP-UPLC t R (keto)=27.011min,t R (enol)=28.871min, purity 99.24%, UV 400nm.

[0117] Example 29: Preparation of Compound 10n

[0118] The preparation process is the same as that of Example 16, except that the coumarin is 3-acetyl-7-ethylaminocoumarin, and the target compound 10n is obtained with a yield of 92% as a yellow solid.

[0119] 1H NMR(400MHz, CDCl3)δ:8.77 and 8.41(s,1H,NH and OH,keto-enoltautomerism,keto(-CONH-) / enol(-HOC=N-)ratio 37 / 63),8.04 and 7.62(s,1H,H-4coumarin),7.31-6.43(m,7H,ArH),4.63-4.58 and 3.78-3.76(m,1H,CH),3.47-3.38(m,4H,2×CH2),2.46(d,J=8.0Hz,2H,CH2),2.18 and 1.94(s,3H,CH3),1.88-1.84(m,1H,CH),1.64(d,J=4.0Hz,3H,CH3),1.27-1.19(m,6H,2×CH3),0.90(d,J=8.0Hz,6H,2×CH3); 13 CNMR(100MHz, CDCl3)δ:176.36,161.15,156.96,151.22,142.09,140.01,139.14,129.94,129.67,129.20,127.63, 118.98,109.29,108.51,97.00,45.13,44.93,41.77,30.21,22.46,22.31,14.40,12.48; HRMS(ESI)m / z:Anal.Calcd for C 28 H 36 N3O3([M+H] + ):434.2399,found:433.2365(M + ,100); Anal.RP-UPLC t R (keto)=27.011min,t R (enol)=28.871min, purity 99.24%, UV 400nm.

[0120] Example 30: Preparation of Compound 11a

[0121] 4.10 g (10 mmol) of the compound 9e obtained in Example 5 was weighed, 5 mL of phosphorus oxychloride was added, and the mixture was refluxed and stirred at 80°C for 6 h. The reaction was detected by TLC until all the starting materials disappeared. The mixture was cooled to room temperature, saturated brine and saturated aqueous sodium bicarbonate solution were added in sequence and stirred for 5 min. Then 50 mL of ethyl acetate was added for extraction. The ethyl acetate phase was collected, dried over anhydrous sodium sulfate, and concentrated. The phase was eluted by column chromatography. The silica gel for the column chromatography was 200-300 mesh. The eluent was a mixture of petroleum ether and ethyl acetate (petroleum ether:ethyl acetate=1:3) to obtain the target compound 11a with a yield of 90% as a white solid.

[0122] 1 H NMR(400MHz, CDCl3)δ:8.48(s,H,H-4 coumarin),7.39-7.11(m,7H,ArH),4.46(q,J=8.0Hz,H,CH),2.45(d,J=4.0Hz,2H,C H2),1.87-1.86(m,1H,CH),1.82(d,J=8.0Hz,3H,CH3),0.89(d,J=8.0Hz,6H,2×CH3); 13 C NMR(100MHz, CDCl3)δ:170.28,160.70,155.89,150.75,143.68,141.18,137.14,.129.68,127.10,121.69 ,121.45,118.67,118.59,114.31,114.07,45.02,37.18,30.17,22.38,19.70; HRMS(ESI)m / z:Anal.Calcd forC 23 H 22 FN2O3([M+H] + ):393.1614,found:393.1613(M + ,100); Anal.RP-UPLC t R =26.713min, purity 99.27%, UV 330nm.

[0123] Example 31: Preparation of Compound 11b

[0124] Using 4.27 g (10 mmol) of compound 9d obtained in Example 4 as raw material, the reaction process was the same as that in Example 30 to obtain the target compound 11b with a yield of 93% as a white solid.

[0125] 1H NMR(400MHz, CDCl3)δ:8.48(s,H,H-4 coumarin),7.60-7.11(m,7H,ArH),4.46(q,J=8.0Hz,H,CH),2.45(d,J=4.0Hz,2H,C H2),1.87-1.84(m,1H,CH),1.82(d,J=8.0Hz,3H,CH3),0.89(d,J=8.0Hz,6H,2×CH3); 13 C NMR(100MHz, CDCl3)δ:170.28,160.63,155.86,152.89,143.36,141.19,137.11,133.89,130.56,129.68 ,128.18,127.10,118.96,118.40,113.98,45.02,37.18,30.17,22.39,19.89; HRMS(ESI)m / z:Anal.Calcd for C 23 H 22 ClN2O3([M+H] + ):409.1319,found:409.1322(M + ,100); Anal.RP-UPLC t R =27.959min, purity99.20%, UV 330nm.

[0126] Example 32: Preparation of Compound 11c

[0127] Using 4.61 g (10 mmol) of compound 9h obtained in Example 8 as raw material, the reaction process was the same as that in Example 30 to obtain the target compound 11c with a yield of 86% as a white solid.

[0128] 1 H NMR(400MHz, CDCl3)δ:8.45(s,H,H-4 coumarin),7.69-7.12(m,6H,ArH),4.46(q,J=8.0Hz,H,CH),2.45(d,J=4.0Hz,2H,C H2),1.87-1.86(m,1H,CH),1.82(d,J=8.0Hz,3H,CH3),0.89(d,J=8.0Hz,6H,2×CH3); 13C NMR(100MHz, CDCl3)δ:170.52,160.29,154.54,148.83,142.90,141.24,137.01,133.73,130.38,129.69 ,127.10,126.70,123.01,119.75,114.71,45.02,37.19,30.17,22.37,19.66; HRMS(ESI)m / z:Anal.Calcd for C 23 H 21 Cl2N2O3([M+H] + ):443.0929,found:443.0933(M + ,100); Anal.RP-UPLC t R =29.108min, purity97.29%, UV 330nm.

[0129] Example 33: Preparation of Compound 11d

[0130] Using 5.50 g (10 mmol) of compound 9i obtained in Example 9 as raw material, the reaction process was the same as that in Example 30 to obtain the target compound 11d with a yield of 90% as a white solid.

[0131] 1 H NMR(400MHz, CDCl3)δ:8.42(s,H,H-4 coumarin),7.98-7.11(m,6H,ArH),4.46(q,J=8.0Hz,H,CH),2.45(d,J=4.0Hz,2H,C H2),1.87-1.84(m,1H,CH),1.82(d,J=8.0Hz,3H,CH3),0.89(d,J=8.0Hz,6H,2×CH3); 13 C NMR(100MHz, CDCl3)δ:170.49,160.25,154.83,150.36,142.81,141.24,139.27,137.02,130.44,129.69 ,127.11,120.19,117.68,114.61,111.54,45.02,37.19,30.17,22.38,19.55; HRMS(ESI)m / z:Anal.Calcd for C 23 H 21 Br2N2O3([M+H] + ):530.9919,found:530.9921(M + ,100); Anal.RP-UPLC tR =29.544min, purity98.94%, UV 330nm.

[0132] Example 34: Preparation of Compound 11e

[0133] Using 4.64 g (10 mmol) of compound 9f obtained in Example 6 as raw material, the reaction process was the same as that in Example 30 to obtain the target compound 11e with a yield of 91% as a white solid.

[0134] 1 H NMR(400MHz, CDCl3)δ:8.45(s,H,H-4 coumarin),7.50-6.83(m,7H,ArH),4.45(q,J=8.0Hz,H,CH),4.06(t,J=8.0Hz,2H,CH2),2.44(d,J=8.0Hz,2H,CH2),1.87-1.84and 1.80-1.78(m,1H,CH),1.81(d,J=8.0Hz,3H,CH3),1.56-1.47(m,2H,CH2),0.99(t,J=8.0Hz,3H,CH3),0.89(d,J=8.0Hz,6H,2×CH3); 13 C NMR (100MHz, CDCl3) δ: 169.67, 164.47, 161.45, 156.89, 156.79, 144.88, 141.04, 137.40, 130.24, 129.62, 127.10, 114. 20,111.61,108.76,101.11,68.73,45.03,37.17,30.92,30.15,22.38,19.76,19.15,13.75; HRMS(ESI)m / z:Anal.Calcd for C 27 H 31 N2O4([M+H] + ):447.2284,found:447.2288(M + ,100); Anal.RP-UPLC t R =30.316min, purity 98.05%, UV 330nm.

[0135] Example 35: Preparation of Compound 11f

[0136] Using 4.06 g (10 mmol) of compound 9b obtained in Example 2 as raw material, the reaction process was the same as that in Example 30 to obtain the target compound 11f with a yield of 92% as a white solid.

[0137] 1 H NMR(400MHz, CDCl3)δ:8.47(s,H,H-4 coumarin),7.45-7.11(m,7H,ArH),4.46(q,J=8.0Hz,H,CH),2.45-2.43(m,5H,1×CH2 1×CH3),1.87-1.84(m,1H,CH),1.82(d,J=4.0Hz,3H,CH3),0.89(d,J=8.0Hz,6H,2×CH3); 13 C NMR(100MHz, CDCl3)δ:170.01,161.15,156.58,152.78,144.89,141.11,137.27,135.20,135.04,129.65,12 8.82,127.12,117.78,116.66,112.65,45.03,37.17,30.17,22.39,20.75,19.74; HRMS(ESI)m / z:Anal.Calcd forC 24 H 25 N2O3([M+H] + ):389.1865,found:389.1867(M + ,100); Anal.RP-UPLC t R =27.415min, purity 99.83%, UV 330nm.

[0138] Example 36: Preparation of Compound 11g

[0139] Using 3.92 g (10 mmol) of compound 9a obtained in Example 1 as raw material, the reaction process was the same as that in Example 30 to obtain the target compound 11 g with a yield of 87% as a white solid.

[0140] 1 H NMR(400MHz, CDCl3)δ:8.53(s,H,H-4 coumarin),7.66-7.11(m,8H,ArH),4.46(q,J=8.0Hz,H,CH),2.45(d,J=4.0Hz,2H,C H2),1.87-1.84(m,1H,CH),1.82(d,J=8.0Hz,3H,CH3),0.89(d,J=8.0Hz,6H,2×CH3); 13C NMR(100MHz, CDCl3)δ:170.06,161.01,156.29,154.60,144.81,141.12,137.26,134.02,129.66,129.19 ,127.10,125.16,118.03,116.95,112.88,45.03,37.18,30.15,22.38,19.73; HRMS(ESI)m / z:Anal.Calcd for C 23 H 23 N2O3([M+H] + ):375.1709,found:375.1709(M + ,100); Anal.RP-UPLC t R =26.348min, purity99.49%, UV 330nm.

[0141] Example 37: Preparation of Compound 11h

[0142] Using 4.78 g (10 mmol) of compound 9j obtained in Example 10 as raw material, the reaction process was the same as that in Example 30 to obtain the target compound 11 with a yield of 86% as a yellow solid.

[0143] 1 H NMR(400MHz, CDCl3)δ:8.44(s,H,H-4 coumarin),7.50-6.82(m,7H,ArH),4.45(q,J=8.0Hz,H,CH),4.06(t,J=8.0Hz,2H,CH2),2.44(d,J=8.0Hz,2H,CH2),1.92-1.83(m,3H,1×CH 1×CH2),1.81(d,J=8.0Hz,3H,CH3),1.49-1.37(m,4H,2×CH2),0.94(t,J=8.0Hz,3H,CH3),0.89(d,J=4.0Hz,6H,2×CH3); 13 C NMR (100MHz, CDCl3) δ: 169.60, 164.46, 161.42, 156.84, 156.76, 144.87, 141.01, 137.41, 130.29, 129.61, 127.10, 114. 18,111.58,108.67,101.9,69.03,45.02,37.14,30.15,28.58,28.07,22.39,19.77,13.99; HRMS(ESI)m / z:Anal.Calcd for C 28 H33 N2O4([M+H] + ):461.2440,found:461.2443(M + ,100); Anal.RP-UPLC t R =31.467min, purity 99.89%, UV 330nm.

[0144] Example 38: Preparation of Compound 11i

[0145] Using 4.92 g (10 mmol) of compound 9k obtained in Example 11 as raw material, the reaction process was the same as that in Example 30 to obtain the target compound 11i with a yield of 94% as a white solid.

[0146] 1 H NMR(400MHz, CDCl3)δ:8.45(s,H,H-4 coumarin),7.50-6.82(m,7H,ArH),4.44(q,J=8.0Hz,H,CH),4.05(t,J=8.0Hz,2H,CH2),2.44(d,J=8.0Hz,2H,CH2),1.87-1.75(m,6H,1×CH 1×CH2 1×CH3),1.49-1.44(m,2H,CH2),1.37-1.35(m,4H,2×CH2),0.93-0.88(m,9H,3×CH3); 13 C NMR(100MHz, CDCl3)δ:169.64,164.46,161.44,156.87,156.76,144.86,141.02,137.41,130.25,129.61,127.10,114.19,111 .60,108.72,101.11,69.05,45.03,37.16,31.49,30.14,28.86,25.59,22.55,22.38,19.77,13.99; HRMS(ESI)m / z:Anal.Calcd for C 29 H 35 N2O4([M+H] + ):475.2597,found:475.2592(M + ,100);Anal.RP-UPLCt R =32.963min, purity 99.35%, UV 330nm.

[0147] Example 39: CCK-8 method to detect the anti-tumor activity of the ibuprofen-coumarin skeleton compound prepared in the above example

[0148] Take cells in the logarithmic growth phase, discard the old culture medium, wash three times with PBS to clean the culture medium and cell metabolic waste, then add 1mL 0.25% trypsin, digest at 37℃ for 1-2min, after digestion, add 1-2mL complete culture medium to terminate digestion, and use a pipette to gently blow off the adherent cells, transfer them to a 15mL centrifuge tube, centrifuge at 1000r / min for 5 minutes, discard the supernatant after centrifugation, add 1-2mL complete culture medium, suspend the cells by blowing with a pipette, aspirate 10μL of cell suspension onto a cell counting plate, cover with a coverslip, and count under a microscope. The cell suspension prepared in the previous step was inoculated in the center 55 wells of a 96-well plate (100 μL / well), and 5 wells were set up with only culture medium as a blank group. The plates were cultured in a 37°C, 5% CO2 incubator for 24 h, and then the culture medium was removed, PBS was added for washing, and culture medium containing 5 different concentrations of the test compound was added. Five replicate wells were set up for each concentration, and 5 replicate wells inoculated with cells were set up with only culture medium as a control group. After the addition of the drug, the plates were cultured for 48 h, the culture medium in the wells was discarded, and culture medium containing 10 μL of enhanced CCK-8 solution was added to each well. The plates were transferred to an incubator and incubated for 4 h at 37°C, 5% CO2. The absorbance (A) at 450 nm was measured using an enzyme reader, and the measurement was repeated three times to take the average value.

[0149] The inhibition rate of the test compound at a certain concentration = [1-(A 药物 -A 空白 ) / (A 对照 -A 空白 )]×100%; import the concentration and inhibition rate data into SPSS software to calculate the IC 50 value;

[0150] The CCK-8 method was used to detect the inhibitory effect of the compound on the proliferation of HepG2 cells and Hela cells. The test results are shown in Table 1, Table 2, and Table 3:

[0151] Table 1 Proliferation inhibitory activity of compounds (9a-9m) on HepG2 and Hela

[0152]

[0153]

[0154] Table 2 Proliferation inhibitory activity of compounds (10a-10k) on HepG2 and Hela

[0155]

[0156]

[0157] Table 3 Proliferation inhibitory activity of compounds (11a-11i) on HepG2 and Hela

[0158]

[0159] It can be seen from the table that: taking gefitinib as the positive control, the ibuprofen-coumarin skeleton-containing compounds of the present invention have potential anti-tumor activity against HepG2 liver cancer cells and Hela cervical cancer cells, and 9e, 9g, 9i, 10d, 10e, 10f, 10h, 10i, 10k, and 11g have better activities, among which 10e is the most excellent, and its activity in inhibiting both cancer cells is better than that of ibuprofen and the commonly used anti-tumor drug gefitinib.

[0160] Example 40: Acetic acid writhing method to detect the analgesic activity of the ibuprofen-coumarin skeleton-containing compound prepared in the above example

[0161] Twenty-four mice were randomly divided into a negative control group, a positive control group, and a treatment group, with 8 mice in each group. The treatment group was gavaged with a compound solution (4 mg / mL) at a dose of 2 mg / 10 g of mouse body weight, the positive control group was gavaged with an ibuprofen solution (4 mg / mL) at a dose of 1 mg / 10 g of mouse body weight, and the negative control group was gavaged with an equal amount of normal saline. 1.5 hours later, 0.7% glacial acetic acid 0.1 mL / 10 g was intraperitoneally injected. The number of twisting times of the mice within 20 minutes after the injection of glacial acetic acid was observed and recorded. This was repeated three times in parallel to calculate the analgesic rate.

[0162] Analgesia rate (%) = (number of writhing reactions of mice in the negative control group - number of writhing reactions of mice in the drug-treated group) / number of writhing reactions of mice in the negative control group × 100%, the results are shown in Table 4;

[0163] Table 4 Analgesic rate of compounds

[0164] Compound Standard Deviation t-test Analgesia rate 9a 5.9462 0.01103015 36.25% 9d 6.8661 0.00066495 80.00% 9f 6.3189 0.03007355 31.25% 9g 5.2576 0.0367161 26.25% 9h 8.2980 0.76018587 5.00% 9i 9.5160 0.01226017 61.88% 9j 4.2426 0.00018658 60.00% 9m 8.0133 0.08670649 28.75% 10a 8.6879 0.00710610 57.71% 10b 6.1818 0.39207902 11.25% 10e 5.8172 0.00011615 84.38% 10g 6.3310 0.00727993 57.30% 10h 6.4904 0.02088597 34.38% 11b 6.0223 0.35814179 -11.88% 11e 5.6315 0.07987136 22.50% 11f 4.9785 0.02013302 28.75% 11h 8.3313 0.01145093 56.88% Normal saline 3.7033 -- -- Ibuprofen 3.2514 <![CDATA[1.26574×10 -7 ]]> 85.00%

[0165] It can be seen from the data in the table that the compounds of the present invention all have analgesic activity, among which 10e and 9d have better analgesic effects, which are comparable to those of ibuprofen.

Claims

1. Use of an ibuprofen-coumarin skeleton compound having a structural formula as shown in the following table in the preparation of an anti-tumor drug; the tumor type is liver cancer; 2. Use of an ibuprofen-coumarin skeleton-containing compound having a structural formula as shown in the following table in the preparation of an anti-tumor drug; the tumor type is cervical cancer;